Nexalin Secures Patent for Intracranial Stimulation Technology

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

Nexalin Secures Patent for Intracranial Stimulation Technology

, MT Newswires - 12:59 PM ET 4/14/2025 default

12:59 PM EDT, 04/14/2025 (MT Newswires) -- Nexalin Technology ( NXL ) said Monday it secured a patent for its deep intracranial frequency stimulation technology in treating substance use disorders.

The firm said the US Patent and Trademark Office granted its patent "Alternating Current Dynamic Frequency Stimulation Method for Opioid Use Disorder and Substance Use Disorder."

The technology may help regulate neural pathways linked to addiction and withdrawal symptoms, offering an alternative treatment pathway, Nexalin ( NXL ) said.

Price: 1.97, Change: +0.08, Percent Change: +4.23

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.